We have developed a unique and powerful combination of techniques (next-generation sequencing of large gene panels and immunohistochemistry analyses, among others) for therapeutic decision-making. We perform these tests on liquid or solid biopsies, analysing relevant somatic or germline alterations.
Our first solution combining DNA, RNA and protein analyses of a tumour tissue sample.
A complete solution integrating the analysis of solid and liquid biopsies.
Smart liquid biopsy panels with selected key genes per tumor type.
The first personalised liquid biopsy in the market.
OncoKDM turns your NGS data into actionable clinical information that you can access via an interactive report. This report includes the NGS quality control results, patient clinical data and variant annotation, as well as treatment and clinical trial options. Moreover, OncoKDM can integrate NGS results with IHC, MSI and TMB data to provide you with an up-to-date and accurate clinical interpretation.
Discover also our Lite offer for OncoKDM.
Our platform OncoSHARE shows you the results of your patient molecular profiling through an online theranostic report that includes a comprehensive biological and clinical interpretation. This report gives you an insight into the most effective treatments according to the unique features of your patient's tumour, taking into account the most relevant scientific information, official cancer guidelines and recruiting clinical trials.
Transforming cancer data into knowledge-driven and useful clinical information
Connecting healthcare professionals and patients
OncoDNA publishes regularly in peer-reviewed international journals.
Here below you will find a selection of key publications supporting our clinical expertise in precision oncology.
Combination of solid and liquid biopsy genomic profiling for tumor heterogeneity characterization
The clinical impact of using complex molecular profiling strategies in routine oncology practice ... [READ MORE]
Thanks to OncoDEEP, we were able to identify a new treatment that would have not been found from routine testing.
Precision medicine is becoming unavoidable for treating cancer. Each patient is unique, and there is a unique way to take care of him/her.